Toggle menu

MAPP2 Study

Start date:
June 2018
End date:
December 2019
Co-ordinated by:
Rachel O'Brien
Main trial site:
Royal Infimary Edinburgh

The development of a new point of care test will detect miR-122 and allow point of care diagnosis of paracetamol toxicity with the aim of improved patient stratification on presentation to hospital and, therefore, improve patient care.

The aim of the study is to establish a biobank of human serum samples from patients with paracetamol overdose to develop and test the performance of our point of care test. This is a prospective, observational cohort study of participants aged 16 years or over presenting to the ED/AMU aiming to recruit 326 participants.

Chief Investigator

Dr James Dear

Consultant in Acute Medicine & Toxicology

Research Team

Rachel O'Brien

Lead Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Claire Cheyne

Senior Research Nurse

More EMERGE Trials

The RECOVERY Trial

Randomised Evaluation of COVID-19 Therapy

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more

NOVEL Study

Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions